Oxidative stress (OS) is involved in several human diseases, including obesity, 
diabetes, atherosclerosis, carcinogenesis, as well as genetic diseases. We 
previously found that OS occurs in Down Syndrome as well as in 
Beckwith-Wiedemann Syndrome (BWS). Here we describe the clinical case of a 
female patient with Prader Willi Syndrome (PWS), a genomic imprinting disorder, 
characterized by obesity, atherosclerosis and diabetes mellitus type 2, 
pathologies in which a continuous and important production of free radicals 
takes place. We verified the presence of OS by measuring a redox biomarkers 
profile including total hydroperoxides (TH), non protein-bound iron (NPBI), 
thiols (SH), advanced oxidation protein products (AOPP) and isoprostanes (IPs). 
Thus we introduced in therapy an antioxidant agent, namely potassium ascorbate 
with ribose (PAR), in addition to GH therapy and we monitored the redox 
biomarkers profile for four years. A progressive decrease in OS biomarkers 
occurred until their normalization. In the meantime a weight loss was observed 
together with a steady growth in standards for age and sex.